atrasentan has been researched along with Proteinuria in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Alpers, CE; Hudkins, KL; Steegh, F; Wietecha, TA | 1 |
| Andreucci, M; De Nicola, L; Garofalo, C; Minutolo, R; Provenzano, M; Serra, R | 1 |
| Egido, J; Gomez-Guerrero, C; Gonzalez Parra, E; Mas, S; Rojas-Rivera, J; Ruiz-Ortega, M; Sanz, AB | 1 |
| Lin, L; Liu, Y; Tan, RJ; Zhou, D; Zhou, L | 1 |
| Chang, NC; Chung, TH; Lee, TM; Lin, SZ | 1 |
| Jeon, Y; Jin, C; Kleven, DT; Pollock, DM; Pollock, JS; White, JJ | 1 |
| Ritz, E; Wenzel, RR | 1 |
| Horio, T; Johnson, RJ; Kangawa, K; Kawano, Y; Suga, S; Yasui, N; Yoshihara, F | 1 |
| Bäcker, A; Cervenka, L; Kramer, HJ; Opocensky, M; Vanêcková, I; Vernerová, Z | 1 |
| Bäcker, A; Cervenka, L; Dvorák, P; Eis, V; Kramer, HJ; Opocenský, M; Schejbalová, S; Vanecková, I; Vernerová, Z | 1 |
| Polakowski, JS; Pollock, DM | 1 |
| Opgenorth, TJ; Polakowski, JS; Pollock, DM; Wegner, CD | 1 |
| Clower, B; Granger, JP; Kassab, S; Miller, MT; Novak, J; Reckelhoff, J | 1 |
| Blezer, EL; Goldschmeding, R; Jansen, GH; Joles, JA; Koomans, HA; Nicolay, K; Rabelink, TJ | 1 |
2 review(s) available for atrasentan and Proteinuria
| Article | Year |
|---|---|
Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease.
Topics: Animals; Atrasentan; Diabetic Nephropathies; Disease Progression; Endothelin A Receptor Antagonists; Humans; Proteinuria; Randomized Controlled Trials as Topic; Receptor, Endothelin A; Renal Insufficiency, Chronic | 2021 |
Atrasentan for the treatment of diabetic nephropathy.
Topics: Animals; Atrasentan; Diabetic Nephropathies; Endothelin Receptor Antagonists; Endothelin-1; Humans; Proteinuria; Pyrrolidines; Renal Insufficiency, Chronic | 2017 |
12 other study(ies) available for atrasentan and Proteinuria
| Article | Year |
|---|---|
Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrasentan; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Losartan; Mice; Phosphorylation; Podocytes; Proteinuria; Renin-Angiotensin System; Ribosomal Protein S6 Kinases; TOR Serine-Threonine Kinases | 2020 |
Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy.
Topics: Animals; Atrasentan; Disease Models, Animal; Doxorubicin; Endothelin A Receptor Antagonists; Fibrosis; Gene Expression; Kidney Diseases; Kidney Glomerulus; Male; Mice; Podocytes; Proteinuria; Pyrrolidines; Receptor, Endothelin A | 2013 |
Endothelin receptor blockade ameliorates renal injury by inhibition of RhoA/Rho-kinase signalling in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Animals; Atrasentan; Blood Pressure; Desoxycorticosterone Acetate; Endothelin Receptor Antagonists; Endothelin-1; Fibrosis; Gene Expression Regulation; Hypertension; Kidney; Male; Proteinuria; Pyrrolidines; Random Allocation; Rats; Rats, Wistar; rho-Associated Kinases; rhoA GTP-Binding Protein; Sodium Chloride, Dietary | 2014 |
Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antihypertensive Agents; Arterial Pressure; Atrasentan; Cell Adhesion Molecules; Chlorthalidone; Deoxyguanosine; Disease Models, Animal; Diuretics; Drug Combinations; Endothelin A Receptor Antagonists; Endothelins; Hypertension; Inflammation; Kidney Diseases; Male; Membrane Proteins; Metabolic Syndrome; Oxidative Stress; Proteinuria; Pyrrolidines; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Receptor, Endothelin A; Sodium Chloride, Dietary | 2014 |
Endothelin antagonist as add-on treatment for proteinuria in diabetic nephropathy: is there light at the end of the tunnel?
Topics: Albuminuria; Atrasentan; Diabetic Nephropathies; Endothelins; Glomerular Filtration Rate; Humans; Proteinuria; Pyridines; Pyrimidines; Pyrrolidines; Renin-Angiotensin System; Treatment Outcome | 2011 |
Endothelin a receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms.
Topics: Albuminuria; Animals; Atrasentan; Endothelin Receptor Antagonists; Endothelin-1; Hypertension; Hypertrophy; Hypokalemia; Kidney; Kidney Diseases; Kidney Tubules; Male; Potassium; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B | 2003 |
Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Endothelin A Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heart Ventricles; Hypertension; Kidney; Male; Myocardium; Organ Size; Osmolar Concentration; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Renin; Sodium Chloride, Dietary; Sulfonamides; Survival Analysis | 2005 |
Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats.
Topics: Animals; Animals, Genetically Modified; Antihypertensive Agents; Atrasentan; Blood Pressure; Body Weight; Bosentan; Cardiomegaly; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Glomerulosclerosis, Focal Segmental; Heterozygote; Hypertension; Male; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Renin; Sodium Chloride, Dietary; Sulfonamides; Time Factors | 2006 |
ETA receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat.
Topics: Administration, Oral; Animals; Atrasentan; Blood Pressure; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Hypertension, Renal; Kidney; Kidney Failure, Chronic; Male; Nephrectomy; Protein Precursors; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A | 1997 |
Beneficial effect of ETA receptor blockade in a rat model of radiocontrast-induced nephropathy.
Topics: Acute Kidney Injury; Animals; Atrasentan; Contrast Media; Creatinine; Diatrizoate; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelins; Indomethacin; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Prostaglandin Antagonists; Proteinuria; Pyrrolidines; Rats; Rats, Sprague-Dawley; Stereoisomerism | 1997 |
Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats.
Topics: Animals; Atrasentan; Blood Pressure; Diet, Sodium-Restricted; Endothelin Receptor Antagonists; Glomerular Filtration Rate; Hemodynamics; Hypertension; Kidney; Male; Natriuresis; Potassium; Proteinuria; Pyrrolidines; Rats; Rats, Inbred Strains; Receptor, Endothelin A; Regional Blood Flow; Sodium; Sodium, Dietary; Systole | 1998 |
Early-onset but not late-onset endothelin-A-receptor blockade can modulate hypertension, cerebral edema, and proteinuria in stroke-prone hypertensive rats.
Topics: Animals; Atrasentan; Blood Pressure; Brain Edema; Data Interpretation, Statistical; Endothelin Receptor Antagonists; Hypertension; Hypertension, Malignant; Kidney; Magnetic Resonance Imaging; Male; Proteinuria; Pyrrolidines; Rats; Rats, Inbred SHR; Sodium Chloride, Dietary; Stereoisomerism; Time Factors | 1999 |